18.98
-0.18(-0.94%)
Currency In USD
| Previous Close | 19.16 |
| Open | 18.92 |
| Day High | 19.43 |
| Day Low | 18.43 |
| 52-Week High | 25.77 |
| 52-Week Low | 3.5 |
| Volume | 820,308 |
| Average Volume | 1.59M |
| Market Cap | 1.24B |
| PE | 59.31 |
| EPS | 0.32 |
| Moving Average 50 Days | 19.41 |
| Moving Average 200 Days | 10.12 |
| Change | -0.18 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $896.13 as of February 21, 2026 at a share price of $18.98. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $2,938.08 as of February 21, 2026 at a share price of $18.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
GlobeNewswire Inc.
Jan 09, 2026 3:49 AM GMT
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwri
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 07, 2026 9:01 PM GMT
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an u
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inf